Human immunodeficiency virus type 1 clade B antigen (HIV-1 clade B antigen)

Human immunodeficiency virus type 1 (HIV-1) clade B antigens represent the structural, enzymatic, and regulatory proteins derived from the most prevalent HIV-1 subtype in the Americas, Europe, and Australia. These antigens, including Env (gp120/gp41), Gag, Pol, and Nef, are the primary targets for the host immune system and are central to the development of vaccines and monoclonal antibodies. The Env protein facilitates viral entry by binding to CD4 receptors and co-receptors (CCR5 or CXCR4), while Gag and Pol are essential for viral assembly and replication. In therapeutic contexts, 'indirect immune-mediated recognition' refers to the process where the immune system is primed by vaccines or exogenous antibodies to identify and destroy cells expressing these clade B antigens. This is achieved through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and the presentation of viral peptides on MHC molecules to T cells. Targeting these antigens is a cornerstone of HIV research, aiming to achieve functional cures or long-term viral suppression by enhancing the body's natural ability to recognize and eliminate the virus.

Other names

HIV-1 subtype B antigensHIV-1 group M subtype B proteinsIndirect immune-mediated recognition of HIV-1 clade B antigens

Vaccines and immunotherapies utilize these antigens to elicit neutralizing antibodies and cytotoxic T-lymphocyte (CTL) responses to inhibit viral entry and clear infected cells.